Cookies on this site

MIST-4 logo University of Oxford logo

Background

Pleural infection is a serious condition in which infected fluid accumulates in the space between the lung and chest wall, often requiring hospital admission, antibiotics, and drainage through a chest tube. In many cases, additional treatment is needed because the infected fluid can become thickened or form pockets that are difficult to clear. Two widely used treatment approaches are intrapleural enzyme therapy (IET), which involves administering medications through the chest tube to break down infected fluid, and video-assisted thoracoscopic surgery (VATS), a minimally invasive surgical procedure to remove the infection. Although both treatments are routinely used in clinical practice, there is currently no high-quality evidence directly comparing their effectiveness. The MIST-4 trial has been designed to address this important clinical question and inform best practice in the management of pleural infection.

Trial Design

MIST-4 is a multicentre, randomised clinical effectiveness trial conducted across hospitals in the UK, aiming to recruit approximately 600 adult patients with pleural infection. Participants are randomly allocated (1:1) to receive either early intrapleural enzyme therapy or early VATS surgery, in addition to standard care including antibiotics and chest drainage. Treatment allocation is determined within 24 hours of diagnosis to enable early intervention. Patients are followed throughout their hospital stay and after discharge, with routine clinical assessments, imaging, and patient-reported outcome measures collected to evaluate recovery. The trial is designed to reflect real-world clinical practice, ensuring that the results are directly applicable to everyday care and will help determine which treatment strategy offers the greatest benefit for patients.

Contact

For further information about the MIST-4 trial, please contact the study team at the Oxford Respiratory Trials Unit:
Email: MIST4@ndm.ox.ac.uk